Getagraph.com logo
S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-1.16%) $1.619
Gold
(0.30%) $2 349.60
Silver
(-0.47%) $27.23
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Realaus laiko atnaujinimai Formycon AG [FYB.DE]

Birža: XETRA Sektorius: Biotechnology Pramonė: Biotechnology
Atnaujinta26 bal. 2024 @ 18:36
25% discount on Stockinvest.us - Use code: Podcast

0.63% € 39.95

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:36):

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials...

Stats
Šios dienos apimtis 4 802.00
Vidutinė apimtis 8 148.00
Rinkos kapitalizacija 705.39M
EPS €0 ( 2024-04-25 )
Kita pelno data ( €0 ) 2024-05-28
Last Dividend €0 ( N/A )
Next Dividend €0 ( N/A )
P/E -10.57
ATR14 €0.0780 (0.20%)

Tūris Koreliacija

Ilgas: 0.01 (neutral)
Trumpas: 0.49 (neutral)
Signal:(58.761) Neutral

Formycon AG Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Formycon AG Koreliacija - Valiuta/Žaliavos

The country flag -0.47
( neutral )
The country flag -0.46
( neutral )
The country flag 0.00
( neutral )
The country flag -0.40
( neutral )
The country flag 0.42
( neutral )
The country flag 0.36
( neutral )

Formycon AG Finansinės ataskaitos

Annual 2022
Pajamos: €42.50M
Bruto pelnas: €12.07M (28.41 %)
EPS: €2.62
FY 2022
Pajamos: €42.50M
Bruto pelnas: €12.07M (28.41 %)
EPS: €2.62
FY 2021
Pajamos: €36.97M
Bruto pelnas: €1.01M (2.72 %)
EPS: €-1.225
FY 2020
Pajamos: €34.23M
Bruto pelnas: €8.76M (25.60 %)
EPS: €-0.539

Financial Reports:

No articles found.

Formycon AG

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.